EVRY, France--(BUSINESS WIRE)--COBRED consortium announces that the EU Commission has awarded a 2,9 M EUR (3,9 M$) grant as part of the 6th Framework Programme to the COBRED project coordinated by BioSystems International.
The COBRED project (www.cobred.eu) aims at discovering colon cancer (CRC) and breast cancer (BC) biomarkers / novel diagnostics for patient follow-up (monitoring markers) by exploiting the capacity of 3 state-of-the-art high-throughput technologies in an integrated systems biology approach. In addition to BioSystems International, the consortium comprises 2 other biotechnology firms (Ipsogen – Marseille, France; Biocrates – Innsbrueck, Austria), 2 large comprehensive cancer centres (Institut Curie - Paris, France; Institut Gustave Roussy, - Villejuif, France) and 3 academic partners (University of Debrecen, Hungary; University of Innsbrueck, Austria; University of Tartu, Estonia); the consultancy firm ARTTIC (Paris, France) will support the consortium for project management.
